What is Vicebio's official website?

Vicebio's website is http://www.vicebio.com

What is Vicebio's industry?

Vicebio's industry is Biotechnology Research

Who are Vicebio's top competitors?

Vicebio's top competitors are , , , , , ,

Vicebio company information, Employees & Contact Information

Explore related pages

Vicebio email format Vicebio management contacts

Related company profiles:

Vicebio is a clinical-stage biopharmaceutical company developing transformative multi-pathogen vaccines for respiratory viral infections. At the core of our work is Vicebio’s groundbreaking Molecular Clamp Technology, which locks viral proteins in their optimal conformation. This innovation enables our vaccines to deliver a unique combination of broad protection, ready-to-use administration, and convenient manufacturing. Our lead program is a best-in-class multivalent vaccine targeting five respiratory diseases, positioning Vicebio as a leader in multipathogen respiratory vaccines.

Employees: 23
Founded: -
Industry: Biotechnology Research
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)
Website: http://www.vicebio.com
Keywords: Vaccines, Structural vaccinology, respiratory viruses, RSV, Influenza, SARS-Cov-2, Metapneumovirus, Parainfluenza.
Competitors: Constructive Bio, BioAge Labs, Genespire, Sanofi, SOLASTA® Bio, NanoSyrinx, LoQus23 Therapeutics Ltd, AstriVax Therapeutics, PACT, Biohaven.

Vicebio Questions

News

Sanofi Makes $1.6 Billion Bet on Vicebio’s Vaccine Technology - Inside Precision Medicine

Sanofi Makes $1.6 Billion Bet on Vicebio’s Vaccine Technology Inside Precision Medicine

Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline - GlobeNewswire

Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline GlobeNewswire

France's Sanofi to acquire biotech firm Vicebio for $1.15 billion - Reuters

France's Sanofi to acquire biotech firm Vicebio for $1.15 billion Reuters

Sanofi tightens grip on RSV, paying $1.15B upfront for Vicebio and boosting its pipeline beyond mRNA - Fierce Biotech

Sanofi tightens grip on RSV, paying $1.15B upfront for Vicebio and boosting its pipeline beyond mRNA Fierce Biotech

Sanofi Makes $1.6B Vaccine Bet With Vicebio Acquisition - BioSpace

Sanofi Makes $1.6B Vaccine Bet With Vicebio Acquisition BioSpace

Sanofi to buy early-stage vaccine maker Vicebio for $1.15B upfront - Endpoints News

Sanofi to buy early-stage vaccine maker Vicebio for $1.15B upfront Endpoints News

Sanofi Buying Vaccine Biotech Company Vicebio For Up To $1.6 Billion - Pulse 2.0

Sanofi Buying Vaccine Biotech Company Vicebio For Up To $1.6 Billion Pulse 2.0

Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition - PMLiVE

Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition PMLiVE

Sanofi to Acquire Vicebio - Contract Pharma

Sanofi to Acquire Vicebio Contract Pharma

Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion - The Wall Street Journal

Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion The Wall Street Journal

Sanofi expanding vaccine portfolio in $1.6B Vicebio buyout - BioWorld MedTech

Sanofi expanding vaccine portfolio in $1.6B Vicebio buyout BioWorld MedTech

Sanofi bets big on Vicebio's vaccine platform in $1.15bn buy - BioXconomy

Sanofi bets big on Vicebio's vaccine platform in $1.15bn buy BioXconomy

French pharma giant Sanofi to acquire British vaccine biotech Vicebio for €1.36B - Silicon Canals

French pharma giant Sanofi to acquire British vaccine biotech Vicebio for €1.36B Silicon Canals

UQ-developed Molecular Clamp technology at the heart of Sanofi's US$1.6b acquisition of Vicebio - Business News Australia

UQ-developed Molecular Clamp technology at the heart of Sanofi's US$1.6b acquisition of Vicebio Business News Australia

Sanofi to buy respiratory vaccine biotech Vicebio for $1.6B - FirstWord Pharma

Sanofi to buy respiratory vaccine biotech Vicebio for $1.6B FirstWord Pharma

Sanofi Extends Respiratory Vaccines Reach With $1.15B Acquisition of Clinical-Stage Vicebio - MedCity News

Sanofi Extends Respiratory Vaccines Reach With $1.15B Acquisition of Clinical-Stage Vicebio MedCity News

Sanofi To Acquire Vicebio - Nasdaq

Sanofi To Acquire Vicebio Nasdaq

Vicebio and its molecular clamp vaccine raise big to tackle respiratory viruses - Labiotech.eu

Vicebio and its molecular clamp vaccine raise big to tackle respiratory viruses Labiotech.eu

Sanofi to buy vaccine-focused biotech Vicebio for $1.15B upfront - statnews.com

Sanofi to buy vaccine-focused biotech Vicebio for $1.15B upfront statnews.com

Sanofi to buy UK vaccines developer Vicebio for $1.6bn - pharmaphorum

Sanofi to buy UK vaccines developer Vicebio for $1.6bn pharmaphorum

Startup Vicebio banks $100M in bid to make ‘cost-effective’ vaccines - BioPharma Dive

Startup Vicebio banks $100M in bid to make ‘cost-effective’ vaccines BioPharma Dive

Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I - Clinical Trials Arena

Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I Clinical Trials Arena

Sanofi Acquires Vicebio for $1.15B, Bolstering Vaccine Pipeline - M&A - HIT Consultant

Sanofi Acquires Vicebio for $1.15B, Bolstering Vaccine Pipeline - M&A HIT Consultant

Sanofi to Buy Vicebio for Up to $1.6 Billion in Vaccine Push - Bloomberg.com

Sanofi to Buy Vicebio for Up to $1.6 Billion in Vaccine Push Bloomberg.com

Vicebio hauls in $100M series B to push RSV combo vaccine through phase 1 - Fierce Biotech

Vicebio hauls in $100M series B to push RSV combo vaccine through phase 1 Fierce Biotech

UK vaccine startup Vicebio snags $100M to take on GSK, Pfizer and Moderna - Endpoints News

UK vaccine startup Vicebio snags $100M to take on GSK, Pfizer and Moderna Endpoints News

UK: Sanofi to acquire next-generation vaccine biotech Vicebio for US$1.6bn - Investors in Healthcare

UK: Sanofi to acquire next-generation vaccine biotech Vicebio for US$1.6bn Investors in Healthcare

Sanofi to buy Vicebio in US$1.6b deal for Aussie-developed vaccine tech - Capital Brief

Sanofi to buy Vicebio in US$1.6b deal for Aussie-developed vaccine tech Capital Brief

Vicebio - The Pharma Letter

Vicebio The Pharma Letter

Sanofi to Acquire Vicebio, for US$1.6 Billion - FinSMEs

Sanofi to Acquire Vicebio, for US$1.6 Billion FinSMEs

Sanofi to acquire Vicebio for up to $1.6B - breakingthenews.net

Sanofi to acquire Vicebio for up to $1.6B breakingthenews.net

Vicebio: $100 Million (Series B) Raised To Develop Novel Vaccines Against Respiratory Viral Infections - Pulse 2.0

Vicebio: $100 Million (Series B) Raised To Develop Novel Vaccines Against Respiratory Viral Infections Pulse 2.0

Billion-dollar deal takes UQ vaccine tech to the world - UQ News

Billion-dollar deal takes UQ vaccine tech to the world UQ News

London MedTech Vicebio to be acquired by Sanofi in £1.2bn deal - BusinessCloud

London MedTech Vicebio to be acquired by Sanofi in £1.2bn deal BusinessCloud

Sanofi to acquire British pharmaceutical company Vicebio for $ 1.6 billion - Eurasia Business News

Sanofi to acquire British pharmaceutical company Vicebio for $ 1.6 billion Eurasia Business News

Sanofi to buy Vicebio for up to US$1.6 billion in vaccine push - The Business Times

Sanofi to buy Vicebio for up to US$1.6 billion in vaccine push The Business Times

Ex-GSK vaccine R&D chief to lead new vax venture, directly challenging former employer - Fierce Biotech

Ex-GSK vaccine R&D chief to lead new vax venture, directly challenging former employer Fierce Biotech

Medicxi-backed Vicebio: vaccines with stability, production advantages - BioCentury

Medicxi-backed Vicebio: vaccines with stability, production advantages BioCentury

Companies like Vicebio

Top Vicebio Employees

Vincent Dodeur

n/a

Waremme, Walloon Region, Belgium, Belgium

View

1
gskbio.com
Dr Craig Belcher MBA GAICD RTTP

Head Of Life Sciences, Ip Commercialisation @Uniquest

Australia, Australia

View

1
uniquest.com.au
Koen Huygens

n/a

N/a

View
Wim Tiest

n/a

Geel, Flemish Region, Belgium, Belgium

View

2
gsk.com, webtopus.net

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles

Get direct phone numbers & mobile contacts

Access company data & employee information

Works directly on LinkedIn - no copy/paste needed

Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Learn More

How It Works

Get a Free Account

Search the #1 Contact Database

Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.

Use our AI-Powered Email Finder

Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.

Have a look at Aeroleads Data

Browse our Data

Company Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Profile Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

List Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Vicebio company information, Employees & Contact Information

Explore related pages

Company Details

Vicebio Questions

What is Vicebio's official website?

What is Vicebio's LinkedIn profile?

How many employees are working in Vicebio right now?

What is Vicebio's industry?

What are Vicebio's top competitors?

What are Vicebio's categories?

When was Vicebio founded?

News

Sanofi Makes $1.6 Billion Bet on Vicebio’s Vaccine Technology - Inside Precision Medicine

Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline - GlobeNewswire

France's Sanofi to acquire biotech firm Vicebio for $1.15 billion - Reuters

Sanofi tightens grip on RSV, paying $1.15B upfront for Vicebio and boosting its pipeline beyond mRNA - Fierce Biotech

Sanofi Makes $1.6B Vaccine Bet With Vicebio Acquisition - BioSpace

Sanofi to buy early-stage vaccine maker Vicebio for $1.15B upfront - Endpoints News

Sanofi Buying Vaccine Biotech Company Vicebio For Up To $1.6 Billion - Pulse 2.0

Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition - PMLiVE

Sanofi to Acquire Vicebio - Contract Pharma

Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion - The Wall Street Journal

Sanofi expanding vaccine portfolio in $1.6B Vicebio buyout - BioWorld MedTech

Sanofi bets big on Vicebio's vaccine platform in $1.15bn buy - BioXconomy

French pharma giant Sanofi to acquire British vaccine biotech Vicebio for €1.36B - Silicon Canals

UQ-developed Molecular Clamp technology at the heart of Sanofi's US$1.6b acquisition of Vicebio - Business News Australia

Sanofi to buy respiratory vaccine biotech Vicebio for $1.6B - FirstWord Pharma

Sanofi Extends Respiratory Vaccines Reach With $1.15B Acquisition of Clinical-Stage Vicebio - MedCity News

Sanofi To Acquire Vicebio - Nasdaq

Vicebio and its molecular clamp vaccine raise big to tackle respiratory viruses - Labiotech.eu

Sanofi to buy vaccine-focused biotech Vicebio for $1.15B upfront - statnews.com

Sanofi to buy UK vaccines developer Vicebio for $1.6bn - pharmaphorum

Startup Vicebio banks $100M in bid to make ‘cost-effective’ vaccines - BioPharma Dive

Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I - Clinical Trials Arena

Sanofi Acquires Vicebio for $1.15B, Bolstering Vaccine Pipeline - M&A - HIT Consultant

Sanofi to Buy Vicebio for Up to $1.6 Billion in Vaccine Push - Bloomberg.com

Vicebio hauls in $100M series B to push RSV combo vaccine through phase 1 - Fierce Biotech

UK vaccine startup Vicebio snags $100M to take on GSK, Pfizer and Moderna - Endpoints News

UK: Sanofi to acquire next-generation vaccine biotech Vicebio for US$1.6bn - Investors in Healthcare

Sanofi to buy Vicebio in US$1.6b deal for Aussie-developed vaccine tech - Capital Brief

Vicebio - The Pharma Letter

Sanofi to Acquire Vicebio, for US$1.6 Billion - FinSMEs

Sanofi to acquire Vicebio for up to $1.6B - breakingthenews.net

Vicebio: $100 Million (Series B) Raised To Develop Novel Vaccines Against Respiratory Viral Infections - Pulse 2.0

Billion-dollar deal takes UQ vaccine tech to the world - UQ News

London MedTech Vicebio to be acquired by Sanofi in £1.2bn deal - BusinessCloud

Sanofi to acquire British pharmaceutical company Vicebio for $ 1.6 billion - Eurasia Business News

Sanofi to buy Vicebio for up to US$1.6 billion in vaccine push - The Business Times

Ex-GSK vaccine R&D chief to lead new vax venture, directly challenging former employer - Fierce Biotech

Medicxi-backed Vicebio: vaccines with stability, production advantages - BioCentury

Companies like Vicebio

Pact

Astrivax Therapeutics

Nanosyrinx

Bioage Labs

Biohaven

Solasta® Bio

Sanofi

Genespire

Constructive Bio

Loqus23 Therapeutics...

Top Vicebio Employees

Vincent Dodeur

n/a

Dr Craig Belcher MBA GAICD RTTP

Head Of Life Sciences, Ip Commercialisation @Uniquest

Koen Huygens

n/a

Wim Tiest

n/a

Free Chrome Extension

Aero Online

Select data to include:

How It Works

Get a Free Account

Search the #1 Contact Database

Use our AI-Powered Email Finder

Have a look at Aeroleads Data